SLC5A2 and diabetic kidney disease: In paragraph form, an example PubMed strategy was: (“Diabetic Kidney Disease” OR “diabetic nephropathy” OR “diabetes” AND “chronic kidney disease”) AND (finerenone OR “nonsteroidal mineralocorticoid receptor antagonist” OR “mineralocorticoid receptor antagonists” OR spironolactone OR eplerenone OR “SGLT2 inhibitor” OR empagliflozin OR dapagliflozin OR canagliflozin OR “GLP-1 receptor agonist” OR liraglutide OR semaglutide) AND (randomized OR randomly OR placebo) AND (cardiovascular OR renal OR kidney OR albuminuria).